2024
Tafenoquine for Relapsing Babesiosis: A Case Series
Krause P, Rogers R, Shah M, Kang H, Parsonnet J, Kodama R, Vannier E. Tafenoquine for Relapsing Babesiosis: A Case Series. Clinical Infectious Diseases 2024, 79: 130-137. PMID: 38814096, PMCID: PMC11259219, DOI: 10.1093/cid/ciae238.Peer-Reviewed Original ResearchRelapsing babesiosisPolymerase chain reactionReal-time polymerase chain reactionImmunocompromised patientsTreatment of Plasmodium vivax malariaPlasmodium vivax malariaModel of acute infectionAntimicrobial agentsBlood smearsAnimal models of acute infectionsWeekly maintenance dosesAcquisition of resistanceAtovaquone-proguanilVivax malariaMalaria prophylaxisMaintenance doseLoading doseCase seriesDelayed clearanceAcute infectionTafenoquinePrevent relapseThin blood smearsLow dosesAnimal modelsAbsence of Anti-Babesia microti antibody in commercial intravenous immunoglobulin (IVIG)
Kostka J, Maharjan A, Kumar S, Hackenyos D, Krause P, Dieckhaus K. Absence of Anti-Babesia microti antibody in commercial intravenous immunoglobulin (IVIG). PLOS Neglected Tropical Diseases 2024, 18: e0012035. PMID: 38484010, PMCID: PMC10965045, DOI: 10.1371/journal.pntd.0012035.Peer-Reviewed Original ResearchConceptsIntravenous immunoglobulinB. microti antibodiesBabesiosis patientsSpectrum of disease severityCommercial intravenous immunoglobulinEffective treatment strategiesSevere organ damageHost antibody responseImmunocompromised patientsAdjunctive therapyOrgan damageTreatment strategiesAcute andClinical trialsMicroti antibodiesAsymptomatic infectionAntibody responseTherapeutic benefitTherapeutic effectPatientsDisease severityAntibodiesImmunofluorescence assayProtozoan infectionsCommercial samples
2023
Immune Control in Repeated Babesia microti Infection in a Patient With B-Cell Deficiency
Little J, Oakley M, Thorner A, Johnston D, Majam V, Liakos A, Novack L, Zheng H, Meredith S, Chou C, Newton B, Soiffer R, Krause P, Baden L, Kumar S. Immune Control in Repeated Babesia microti Infection in a Patient With B-Cell Deficiency. Open Forum Infectious Diseases 2023, 11: ofad568. PMID: 38213635, PMCID: PMC10783156, DOI: 10.1093/ofid/ofad568.Peer-Reviewed Original ResearchB-cell deficiencyParasite burdenHuman babesiosisBabesia microti infectionHigher antibody levelsMild clinical symptomsSevere B cell deficiencyB cell populationsT memory stem cellsMemory stem cellsPeak parasite burdenClinical immunityImmune controlImmunologic findingsNK cellsAntibody levelsClinical symptomsMicroti infectionB cellsPatientsSpecific antibodiesStem cellsBabesiosisImmunologyDeficiencyTransfusion-transmitted Babesia spp.: a changing landscape of epidemiology, regulation, and risk mitigation
Drews S, Kjemtrup A, Krause P, Lambert G, Leiby D, Lewin A, O'Brien S, Renaud C, Tonnetti L, Bloch E. Transfusion-transmitted Babesia spp.: a changing landscape of epidemiology, regulation, and risk mitigation. Journal Of Clinical Microbiology 2023, 61: e01268-22. PMID: 37750699, PMCID: PMC10595070, DOI: 10.1128/jcm.01268-22.Peer-Reviewed Original ResearchConceptsBlood productsWhole blood-derived platelet concentratesNon-endemic areasNon-endemic regionsTTB casesMost patientsRed blood cellsClinical presentationSevere illnessBlood donorsDead-end hostsTick-borne parasitesHuman transmissionEndemic regionsClinical settingEpidemiologyBlood cellsCase numbersPlatelet concentratesTransfusionRiskNeurologic Complications of Babesiosis, United States, 2011–2021 - Volume 29, Number 6—June 2023 - Emerging Infectious Diseases journal - CDC
Locke S, O’Bryan J, Zubair A, Rethana M, Moffarah A, Krause P, Farhadian S. Neurologic Complications of Babesiosis, United States, 2011–2021 - Volume 29, Number 6—June 2023 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2023, 29: 1127-1135. PMID: 37209667, PMCID: PMC10202888, DOI: 10.3201/eid2906.221890.Peer-Reviewed Original ResearchConceptsNeurologic complicationsNeurologic symptomsRisk factorsYale-New Haven HospitalInfectious Diseases journal - CDCHigh-grade parasitemiaNeurologic risk factorsRange of symptomsAdult patientsRenal failureDiabetes mellitusFrequent symptomsHospital admissionImpaired consciousnessMedical recordsEndemic areasParasitic infectionsPatientsSymptomsIntraerythrocytic protozoaComplicationsBabesiosisNew HavenDeliriumMellitusHuman Borrelia miyamotoi Infection in North America
Burde J, Bloch E, Kelly J, Krause P. Human Borrelia miyamotoi Infection in North America. Pathogens 2023, 12: 553. PMID: 37111439, PMCID: PMC10145171, DOI: 10.3390/pathogens12040553.Peer-Reviewed Original ResearchClinical manifestationsLyme diseasePersonal protective strategiesCommon clinical manifestationsBlood smear examinationFebrile illnessSmear examinationLaboratory confirmationEndemic areasInfectionProtective strategiesPreventive measuresDiseaseBodied ticksManifestationsProtective clothingBorreliaTicksArthralgiaMyalgiaNauseaComplicationsHeadacheCeftriaxoneFeverThe impact of ABO and RhD blood types on Babesia microti infection
Jajosky R, O’Bryan J, Spichler-Moffarah A, Jajosky P, Krause P, Tonnetti L. The impact of ABO and RhD blood types on Babesia microti infection. PLOS Neglected Tropical Diseases 2023, 17: e0011060. PMID: 36696414, PMCID: PMC9901808, DOI: 10.1371/journal.pntd.0011060.Peer-Reviewed Original ResearchConceptsB. microti infectionABO blood typeBabesia microti infectionMicroti infectionBlood donorsBlood typeDisease severityPlasmodium falciparum malaria patientsFalciparum malaria patientsHigher peak parasitemiaRed blood cell antigensType BImpact of ABOBlood cell antigensBlood type BMalaria patientsTransfusion strategyInfected donorsRhD blood typeSevere diseasePeak parasitemiaB antigensCell antigensPossible associationRhD antigen
2022
Animal models of the immunology and pathogenesis of human babesiosis
Kumar A, Kabra A, Igarashi I, Krause P. Animal models of the immunology and pathogenesis of human babesiosis. Trends In Parasitology 2022, 39: 38-52. PMID: 36470781, DOI: 10.1016/j.pt.2022.11.003.Peer-Reviewed Original ResearchConceptsAnimal modelsHuman babesiosisBabesia infectionImmunological mechanismsModerate diseaseOrgan dysfunctionPathologic responseDisease complicationsAsymptomatic infectionSevere diseaseAnimal studiesInfectionPathological processesDiseaseBabesiosisBabesia speciesAnimalsDomestic animalsComplicationsDysfunctionPathogenesisImmunologyComparing the Epidemiology and Health Burden of Lyme Disease and Babesiosis Hospitalizations in the United States
Bloch E, Zhu X, Krause P, Patel E, Grabowski M, Goel R, Auwaerter P, Tobian A. Comparing the Epidemiology and Health Burden of Lyme Disease and Babesiosis Hospitalizations in the United States. Open Forum Infectious Diseases 2022, 9: ofac597. PMID: 36467296, PMCID: PMC9709699, DOI: 10.1093/ofid/ofac597.Peer-Reviewed Original ResearchNational Inpatient SampleLyme diseaseMale patientsAnnual incidenceHealth burdenLonger hospital stayMean hospital chargesHigher inpatient costsHospital-level variablesStratified systematic random sampleUS Census Bureau dataPerson/yearHospital stayPatient demographicsHospital admissionClinical outcomesHospital chargesInpatient costsInpatient hospitalizationInpatient SampleAdmission costsHospitalizationUS hospitalsDisease severitySystematic random sampleThe utility of a maximum entropy species distribution model for Ixodes scapularis in predicting the public health risk of Lyme disease in Ontario, Canada.
Burrows H, Slatculescu AM, Feng CX, Clow KM, Guillot C, Jardine CM, Leighton PA, Krause PJ, Kulkarni MA. The utility of a maximum entropy species distribution model for Ixodes scapularis in predicting the public health risk of Lyme disease in Ontario, Canada. Ticks And Tick-borne Diseases 2022, 13: 101969. PMID: 35640345, DOI: 10.1016/j.ttbdis.2022.101969.Peer-Reviewed Original ResearchHuman Babesiosis.
Waked R, Krause PJ. Human Babesiosis. Infectious Disease Clinics Of North America 2022, 36: 655-670. PMID: 36116841, DOI: 10.1016/j.idc.2022.02.009.Peer-Reviewed Original ResearchCardiac Complications of Human Babesiosis
Spichler-Moffarah A, Ong E, O’Bryan J, Krause PJ. Cardiac Complications of Human Babesiosis. Clinical Infectious Diseases 2022, 76: e1385-e1391. PMID: 35983604, PMCID: PMC10169432, DOI: 10.1093/cid/ciac525.Peer-Reviewed Original ResearchConceptsYale-New Haven HospitalCardiac complicationsRisk factorsIntensive care unit stayCardiovascular disease risk factorsHuman babesiosisCommon cardiac complicationHigh-grade parasitemiaLife-threatening complicationsDisease risk factorsLonger median lengthQT interval prolongationHigh mortality rateUnit stayComplication groupTick-borne diseaseAdult patientsCardiac outcomesMost patientsThin blood smearsHeart failureInterval prolongationModerate illnessRecord reviewAtrial fibrillationCorrection: Kumar et al. The Global Emergence of Human Babesiosis. Pathogens 2021, 10, 1447
Kumar A, O’Bryan J, Krause PJ. Correction: Kumar et al. The Global Emergence of Human Babesiosis. Pathogens 2021, 10, 1447. Pathogens 2022, 11: 923. PMID: 36015072, PMCID: PMC9415982, DOI: 10.3390/pathogens11080923.Peer-Reviewed Original ResearchBorrelia miyamotoi Meningoencephalitis in an Immunocompetent Patient
Gandhi S, Narasimhan S, Workineh A, Mamula M, Yoon J, Krause PJ, Farhadian SF. Borrelia miyamotoi Meningoencephalitis in an Immunocompetent Patient. Open Forum Infectious Diseases 2022, 9: ofac295. PMID: 35873293, PMCID: PMC9301576, DOI: 10.1093/ofid/ofac295.Peer-Reviewed Original ResearchBroad Antimicrobial Resistance in a Case of Relapsing Babesiosis Successfully Treated With Tafenoquine
Rogers R, Krause PJ, Norris AM, Ting MH, Nagami EH, Cilley B, Vannier E. Broad Antimicrobial Resistance in a Case of Relapsing Babesiosis Successfully Treated With Tafenoquine. Clinical Infectious Diseases 2022, 76: 741-744. PMID: 35684960, DOI: 10.1093/cid/ciac473.Peer-Reviewed Original ResearchCorrection: Kumar et al. The Global Emergence of Human Babesiosis. Pathogens 2021, 10, 1447
Kumar A, O’Bryan J, Krause PJ. Correction: Kumar et al. The Global Emergence of Human Babesiosis. Pathogens 2021, 10, 1447. Pathogens 2022, 11: 607. PMID: 35631130, PMCID: PMC9147755, DOI: 10.3390/pathogens11050607.Peer-Reviewed Original ResearchFrequency and Geographic Distribution of Borrelia miyamotoi, Borrelia burgdorferi, and Babesia microti Infections in New England Residents.
Johnston D, Kelly JR, Ledizet M, Lavoie N, Smith RP, Parsonnet J, Schwab J, Stratidis J, Espich S, Lee G, Maciejewski KR, Deng Y, Majam V, Zheng H, Bonkoungou SN, Stevens J, Kumar S, Krause PJ. Frequency and Geographic Distribution of Borrelia miyamotoi, Borrelia burgdorferi, and Babesia microti Infections in New England Residents. Clinical Infectious Diseases 2022 PMID: 35325084, DOI: 10.1093/cid/ciac107.Peer-Reviewed Original ResearchBabesia microti infectionB. miyamotoiMicroti infectionB. burgdorferiB. microtiAcute undifferentiated febrile illnessCross-sectional seroprevalence studyBorrelia miyamotoiUndifferentiated febrile illnessB. miyamotoi infectionBorrelia burgdorferiLevel of seroprevalenceIxodes scapularis ticksFebrile illnessTickborne infectionMiyamotoi infectionSeroprevalence studyHuman infectionsIxodes pacificus ticksClinical casesInfectionSerum samplesAverage seroprevalenceSpecific antibodiesScapularis ticksEpidemiology of Hospitalized Patients with Babesiosis, United States, 2010–2016 - Volume 28, Number 2—February 2022 - Emerging Infectious Diseases journal - CDC
Bloch EM, Day JR, Krause PJ, Kjemtrup A, O’Brien S, Tobian AAR, Goel R. Epidemiology of Hospitalized Patients with Babesiosis, United States, 2010–2016 - Volume 28, Number 2—February 2022 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2022, 28: 354-362. PMID: 35076004, PMCID: PMC8798708, DOI: 10.3201/eid2802.210213.Peer-Reviewed Original ResearchConceptsNational Inpatient Sample databaseInfectious Diseases journal - CDCAnalysis of hospitalizationsHospitalized patientsAdvanced ageMortality rateHospitalizationSample databaseObservation periodEpidemiologyHigher severityPatientsBabesiosisDiagnosisUnited StatesReporting dataBabesiaAdmissionIllnessIncidenceDiseaseSeverity
2021
The Global Emergence of Human Babesiosis
Kumar A, O’Bryan J, Krause PJ. The Global Emergence of Human Babesiosis. Pathogens 2021, 10: 1447. PMID: 34832603, PMCID: PMC8623124, DOI: 10.3390/pathogens10111447.Peer-Reviewed Original ResearchHuman babesiosisPrimary clinical characteristicsEndemic diseaseGlobal health burdenHard-bodied ticksMode of transmissionFulminant casesTick-borne diseaseClinical characteristicsBlood transfusionDisease locationHealth burdenOrgan transplantationEpidemiologic toolIntraerythrocytic protozoaDiseaseBabesiosisInfectionLike agentsGlobal emergenceHuman pathogensUnited StatesBabesiaWide spectrumPredominant speciesBabesiosis
Chen T, Mamoun C, Krause P. Babesiosis. 2021, 1298-1304. DOI: 10.1093/med/9780190888367.003.0200.Peer-Reviewed Original ResearchB. microtiHard-bodied ticksHuman granulocytic anaplasmosisPowassan virusEtiologic agentIntraerythrocytic protozoaLyme diseaseBorrelia miyamotoiGranulocytic anaplasmosisBabesia infectionBorrelia burgdorferiDiseaseZoonotic diseaseB. duncaniAnaplasma phagocytophilumApicomplexa phylumInfectionMicrotiB. venatorumB. divergensBabesia sppBabesiosisIxodes scapularisPrimary vectorFever